Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment

References

• Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011;117:7121–7125.
   PubMed Web of Science ®Google Scholar
• Costa D, Valera S, Carrio A, et al. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do? Leuk Res 2010;34:1437–1441.
   PubMed Web of Science ®Google Scholar
• Ketterling RP, Wyatt WA, VanWier SA, et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of ‘FISH panel testing’ and M-FISH. Leuk Res 2002;26:235–240.
   PubMed Web of Science ®Google Scholar
• Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes –proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 2014;28:1793–1798.
   PubMed Web of Science ®Google Scholar
• Nybakken GE, Bagg A. The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes. J Mol Diagn 2014;16:145–158.
   PubMed Web of Science ®Google Scholar
• Tiu RV, Gondek LP, O’Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011;117:4552–4560.
   PubMed Web of Science ®Google Scholar
• Kohlmann A, Klein HU, Weissmann S, et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011;25:1840–1848.
   PubMed Web of Science ®Google Scholar
• Bruning RD, Germing U. Myelodysplastic syndromes. In: Orazi A, ed. Knowles’ neoplastic hematopathology: Wolters Kluwer/Lippincott Williams & Wilkins; 2014:1076–1107.
   Google Scholar
• Lai JL, Preudhomme C, Zandecki M, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995;9:370–381.
   PubMed Web of Science ®Google Scholar
• Jotterand Bellomo M, Parlier V, Muhlematter D, et al. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet 1992;59:138–160.
   PubMed Web of Science ®Google Scholar
• Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451(7176):335–339.
   PubMed Web of Science ®Google Scholar
• Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle 2010;9:855–856.
   PubMed Web of Science ®Google Scholar
• Gaballa MR, Besa EC. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Ann Hematol 2014;93:723–733.
   PubMed Web of Science ®Google Scholar
• Saft L, Karimi M, Ghaderi M, et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica 2014;99: 1041–1049.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820–829.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28:241–247.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:3616–3627; quiz 3699.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Shao J, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27: 1275–1282.
   PubMed Web of Science ®Google Scholar
• Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res 2015;39:6–17.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496–2506.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118: 6239–6246.
   PubMed Web of Science ®Google Scholar
• Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371:2477–2487.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. New Engl J Med 2014;371:2488–2498.
   PubMed Web of Science ®Google Scholar
• Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Med 2014;20:1472–1478.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30:3376–3382.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Kuo YY, Hou HA, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 2012;120:3106–3111.
   PubMed Web of Science ®Google Scholar
• Harada H, Harada Y. Recent advances in myelodysplastic syndromes: molecular pathogenesis and its implications for targeted therapies. Cancer Sci 2015;106:329–336.
   PubMed Web of Science ®Google Scholar
• Weinzierl EP, Arber DA. The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. Am J Clin Pathol 2013;139:9–29.
   PubMed Web of Science ®Google Scholar
• Hunt KE, Salama ME, Sever CE, et al. Bone marrow examination for unexplained cytopenias reveals nonspecific findings in patients with collagen vascular disease. Arch Pathol Lab Med 2013;137: 948–954.
   PubMed Web of Science ®Google Scholar
• Magalhaes S, Pinheiro DA, Souza MD, et al. The relationship between the thyroid hormone (or its lack) and dysplastic hematopoiesis. J Cancer Res Ther 2008;4:102–103.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Kulasekararaj AG, Al Ali AH, et al. Characteristics and outcome of myelodysplastic syndromes (MDS) patients with autoimmune diseases. Conference Abstract: https://ash.confex.com/ash/2013/webprogram/Paper60867.ht ASH 2013 Annual Meeting. New Orleans; 2013.
   Google Scholar
• Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia—a review. Br J Haematol 2008;140:123–132.
   PubMed Web of Science ®Google Scholar
• Watt CD, Roullet MR, Bagg A. Application of molecular genetics to the diagnosis and classification of hematologic neoplasm. In: Orazi A, ed. Knowles's neoplastic hematopathology. Third edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2014:194–231.
   Google Scholar
• Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 2015;29:66–75.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica 2009;94:264–268.
   PubMed Web of Science ®Google Scholar
• Buesche G, Teoman H, Wilczak W, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 2008;22:313–322.
   PubMed Web of Science ®Google Scholar
• Schmidt AE, Oh ST, Education Committee of the Academy of Clinical Laboratory P, Scientists. Pathology consultation on myeloproliferative neoplasms. Am J Clin Pathol 2012;138:12–19.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365(9464):1054–1061.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207–1209.
   PubMed Web of Science ®Google Scholar
• Ingram W, Lea NC, Cervera J, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006;20:1319–1321.
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program 2008:52–59.
   PubMedGoogle Scholar
• Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011; 29:504–515.
   PubMed Web of Science ®Google Scholar
• Viny AD, Levine RL. Genetics of myeloproliferative neoplasms. Cancer J 2014;20:61–65.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Tefferi A, Levine RL. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am 2012;26:1053–1064.
   PubMed Web of Science ®Google Scholar
• Neumann M, Heesch S, Schlee C, et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 2013;121:4749–4752.
   PubMed Web of Science ®Google Scholar
• Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nature Genetics 2014;46:171–175.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384–1395.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119: 569–572.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25: 3503–3510.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–1465.
   PubMed Web of Science ®Google Scholar
• Wei S, Chen X, McGraw K, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2013;32:1110–1120.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol 2014;32: 2691–2698.
   PubMed Web of Science ®Google Scholar
• Muller-Thomas C, Rudelius M, Rondak IC, et al. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2014;99:e179–181.
   Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:1147–1152.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Fernandez-Mercado M, Di Genua C, et al. Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia. Leukemia 2014;28: 1148–1151.
   PubMed Web of Science ®Google Scholar
• Thol F, Winschel C, Ludeking A, et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 2011;96:1870–1873.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7): 1153–1158.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289–2301.
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605–613.
   PubMed Web of Science ®Google Scholar
• Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 2012;119:5824–5831.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 2013;121:4769–4777.
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24:1094–1096.
   PubMed Web of Science ®Google Scholar
• Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010;24:1062–1065.
   PubMed Web of Science ®Google Scholar
• Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genetics 2010;42:665–667.
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics 2010;42:722–726.
   PubMed Web of Science ®Google Scholar
• Jerez A, Sugimoto Y, Makishima H, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 2012;119:6109–6117.
   PubMed Web of Science ®Google Scholar
• Dicker F, Haferlach C, Sundermann J, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010;24:1528–1532.
   PubMed Web of Science ®Google Scholar
• Makishima H, Cazzolli H, Szpurka H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009;27: 6109–6116.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478(7367): 64–69.
   PubMed Web of Science ®Google Scholar
• Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119:3578–3584.
   PubMed Web of Science ®Google Scholar
• Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics 2012;44:53–57.
   Web of Science ®Google Scholar
• Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 1998;12:887–892.
   PubMed Web of Science ®Google Scholar
• Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011;29:1971–1979.
   PubMed Web of Science ®Google Scholar
• Bains A, Luthra R, Medeiros LJ, et al. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol 2011;135:62–69.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Invernizzi R. Molecular basis of congenital dyserythropoietic anemia type II and genotype-phenotype relationship. Haematologica 2010;95:693–695.
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Harigae H. Pathophysiology and genetic mutations in congenital sideroblastic anemia. Pediatr Int 2013;55:675–679.
   PubMed Web of Science ®Google Scholar
• Irving JA, Mattman A, Lockitch G, et al. Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. CMAJ 2003;169:129–131.
   PubMed Web of Science ®Google Scholar
• Karunajeewa H, Wall A, Metz J, et al. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease. Aust N Z J Med 1998;28:215–216.
   PubMedGoogle Scholar
• Bain BJ, Clark DM, Wilkins BS. Bone marrow pathology, 4th edn. New York: Wiley-Blackwell; 2010.
   Google Scholar
• Rezuke WN, Anderson C, Pastuszak WT, et al. Arsenic intoxication presenting as a myelodysplastic syndrome: a case report. Am J Hematol 1991;36:291–293.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues 4th edn. Lyon, France: International Agency for Research on Cancer; 2008.
   Google Scholar
• Foucar K. Bone marrow manifestations of noninfectious systemic diseases. In: Foucar K, Reichard K, Czuchlewski D, eds. Bone marrow pathology. Chicago: ASCP Press; 2010:775–777.
   Google Scholar
• Kaloutsi V, Kohlmeyer U, Maschek H, et al. Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious diseases. Am J Clin Pathol 1994;101:123–129.
   PubMed Web of Science ®Google Scholar
• Brunning RD, Porwit A, Orazi A. Myelodysplastic syndromes/neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymhoid tissues. Lyon, France: International Agency for Research on Cancer Press; 2008:87–104.
   Google Scholar